Top Ranked Momentum Stocks to Buy for March 13th
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 13th:
GSX Techedu Inc. (GSX): This technology-driven education company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days.
GSX Techedu Inc. Unsponsored ADR Price and Consensus
GSX Techedu Inc. Unsponsored ADR price-consensus-chart | GSX Techedu Inc. Unsponsored ADR Quote
GSX Techedu’s shares gained 16.2% over the last one month above the S&P 500’s decrease of 26.6%. The company possesses a Momentum Score of B.
GSX Techedu Inc. Unsponsored ADR Price
GSX Techedu Inc. Unsponsored ADR price | GSX Techedu Inc. Unsponsored ADR Quote
Arcus Biosciences, Inc. (RCUS): This clinical-stage biopharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.8% over the last 60 days.
Arcus Biosciences, Inc. Price and Consensus
Arcus Biosciences, Inc. price-consensus-chart | Arcus Biosciences, Inc. Quote
Arcus Biosciences’ shares gained 50.7% over the last one month. The company possesses a Momentum Score of B.
Arcus Biosciences, Inc. Price
Arcus Biosciences, Inc. price | Arcus Biosciences, Inc. Quote
Virtu Financial, Inc. (VIRT): This provider of market making and liquidity services has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 18.4% over the last 60 days.
Virtu Financial, Inc. Price and Consensus
Virtu Financial, Inc. price-consensus-chart | Virtu Financial, Inc. Quote
Virtu Financial’s shares gained 36.2% over the last one month. The company possesses a Momentum Score of B.
Virtu Financial, Inc. Price
Virtu Financial, Inc. price | Virtu Financial, Inc. Quote
Bicycle Therapeutics plc (BCYC): This clinical-stage biopharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 27% over the last 60 days.
Bicycle Therapeutics PLC Sponsored ADR Price and Consensus
Bicycle Therapeutics PLC Sponsored ADR price-consensus-chart | Bicycle Therapeutics PLC Sponsored ADR Quote
Bicycle Therapeutics’ shares gained 32.9% over the last one month. The company possesses a Momentum Score of B.
Bicycle Therapeutics PLC Sponsored ADR Price
Bicycle Therapeutics PLC Sponsored ADR price | Bicycle Therapeutics PLC Sponsored ADR Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Virtu Financial, Inc. (VIRT) : Free Stock Analysis Report
Arcus Biosciences, Inc. (RCUS) : Free Stock Analysis Report
GSX Techedu Inc. Unsponsored ADR (GSX) : Free Stock Analysis Report
Bicycle Therapeutics PLC Sponsored ADR (BCYC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
